Maximize your thought leadership

Helus Pharma Reports Q2 2027 Results, Advances Phase 3 Pipeline for Depression and Anxiety

By Burstable Editorial Team•
Helus Pharma's fiscal Q2 2027 results show a $171.1 million cash position and progress in its Phase 3 program for HLP003, a potential new treatment for major depressive disorder.
Helus Pharma Reports Q2 2027 Results, Advances Phase 3 Pipeline for Depression and Anxiety

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has reported financial results and business updates for its fiscal second quarter ended Sept. 30, 2026. The clinical-stage pharmaceutical company, which is developing novel serotonergic agonists (NSAs) to treat depression, anxiety, and other mental health conditions, highlighted continued advancement of its pipeline and a strengthened cash position.

As of Sept. 30, 2026, Helus Pharma held $171.1 million in cash. The company reported a net loss of $103.1 million for the quarter, compared with $33.7 million in the prior-year period. Operating expenses excluding share-based compensation rose to $39.6 million from $28.5 million, primarily due to the continued advancement of its Phase 3 clinical program. Cash used in operating activities totaled $35.3 million, compared with $34.5 million a year earlier.

During the quarter, Helus Pharma completed enrollment in APPROACH, its pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder (MDD). Enrollment also continued in the EMBRACE and EXTEND studies. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address the large unmet need in depression treatment.

Looking ahead, Helus Pharma plans to initiate a Phase 2 monotherapy study of HLP004 for generalized anxiety disorder in the first quarter of 2027 and expects to select a development candidate for its HLP005 program in the second half of 2027. These milestones reflect the company's commitment to expanding its pipeline of proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.

The company's progress is being closely watched in the biotechnology sector, where new treatments for mental health conditions are in high demand. Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. With operations in Canada, the United States, the United Kingdom, and Ireland, the company is well-positioned to advance its clinical programs.

For more information about Helus Pharma, visit www.helus.com. The full press release can be viewed at https://ibn.fm/yu74F.

The announcement was disseminated by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.

Burstable Editorial Team

Burstable Editorial Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.